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Abstract 
Introduction: The S100 protein family plays an impor tant role in several types of tumors. One of the family 
members is the S100A12 protein, recently known as a new marker in tumorigenicity and gastric cancer research. 
Considering the diagnostic importance of S100A12 and the relatively high prevalence of gastric cancer in Iran, this study 
aimed at examining the expression of S100A12 in the tissues of such patients. 
Method: The expression of S100A12 in 79 Gastr ic Cancer  patients was examined using immunohistochemistry in 
tumor tissue cells, and 50 non-tumor samples were selected for comparison with tumor tissues. Data analysis was 
conducted using SPSS v16 and chi-square test with a confidence interval of 95 percent. 
Results: The results showed that there was a significant difference between tumor  tissues and non -tumor tissues 
with regard to the expression of S100A12 protein, with tumor cells showing significantly lower expression. Based on 
clinicopathologic results, S100A12 protein indicated a negative correlation with tumor dimensions, tumor invasion depth, 
metastasis stage of tumor, and no significant correlation with other clinicopathologic features, like age, sex and 
metastasis to lymph nodes. 
Conclusion: The results showed that the low expression of S100A12 as a new marker  was associated with tumor  
formation and Gastric Cancer progression. 
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Introduction 
The S100 protein family is the largest subfamily 
of calcium-bound proteins [1] that execute key 
functions in the cell, including calcium 
homeostasis, cell proliferation, cell death, protein 
phosphorylation, transcription factor regulation, 
and inflammation [2, 3]. Most of the S100 protein 
genes are located on the human chromosome 1 
q21, which is an area susceptible to genomic 
rearrangements, suggesting that S100 proteins 
may interfere with the progression of the tumor. 
Also, the modified expression of several members 
of the S100 family including S100A2 [2 , 3], 
S100A14 [4], and S100A4 [5] in various types of 
cancers have been shown. The high expression of 
several S100 proteins, such as S100A2, S100A3, 
S100A6, S100A8 / A9, and S100A11 has been 
demonstrated in a variety of cancers. By contrast, 
the low expression of these proteins has been 
exhibited in other types of cancer. The high 
expression of S100A2 is a poor prognostic marker 
for NSCLC and pancreatic cancer [6]. S100A4 is 
commonly expressed in a variety of cancers, and 
the high expression of S100A4 in the progression 
of tumor, invasion, metastasis, survival and poor 
prognosis have been demonstrated in different 
cancers [7]. S100 proteins exert their effects 
through specific target proteins. For example, 
intracellular S100 proteins affect the 
transcriptional activity of P53 protein, which 
ultimately affects the cell cycle regulation applied 
by P53. It has also been shown that some of these 
proteins impose varying effects on specific target 
proteins such as NF-κB and β-catenin, which are 
the pathways for inflammation and cell 
proliferation [2][8-10]. RAGE is a common 
receptor of S100 proteins. It is a cell-receptor that 
plays a major role in inflammation and cancer 
[11]. Studies have suggested that S100 proteins 
have an integral role in angiogenesis by affecting 
molecules such as MMP, TGF-β and FGF, which 
ultimately affect tumor metastasis [12].  
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One member of the S100 protein family is a 
protein called S100A12, which has recently been 
introduced as a new marker of tumorigenicity and 
gastric cancer (GC) progression [13]. The 
S100A12 protein, also known as Calgranulin C, 
has high expressions in neutrophilic granulocytes 
and low expressions in lymphocytes and 
monocytes, while its expression in gastro-intestinal 
epithelial cells and fibroblasts is stimulated during 
inflammation [14]. Elevated serum level of 
S100A12 in acute and chronic inflammatory 
diseases is regarded as a biomarker [15, 16]. 
Recent studies have shown that S100A12 proteins 
play a vital role in detection of Intestinal 
inflammation caused by Crohn's disease and other 
inflammatory bowel diseases [16-18]. It also plays 
a protective role at various stages of atherogenesis 
development by inhibiting pro-inflammatory 
cytokines [19]. Recent studies have exhibited that 
increasing the expression of S100A12 protein can 
be a good diagnostic factor in the survival rate of 
patients with oropharyngeal squamous cell 
carcinomas (OPSCC) [20] In addition, the 
expression of this protein in suprabasal 
keratinocyte of normal mucosa cells is higher, 
while in 30.4% -51.9% of the primary cancer cells 
of OPSCCs, lower expression has been indicated. 
Moreover, this study suggested that the expression 
of this protein and the clinicopathological features 
of the tumor, such as tumor grade, metastasis to 
lymph nodes, and TNM [20].  
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In another study, however, proteomic studies 
showed that S100A12 shows a higher expression 
in colorectal cancer cells compared to normal 
tissues [21]. It has also been exhibited that in non-
cancerous gastric mucosal tissues, S100A12 
protein is present in not only gastric mucosal 
epithelial cells, but also in stem cells such as 
neutrophilic granulocytes, lymphocyte cells and 
monocytes. In addition, the association between 
the expression of this protein and the 
clinicopathologic features of patients with gastric 
cancer has been demonstrated [22]. Gastric cancer 
is recognized as the fourth most common types of 
cancer, and the second most fatal cancer 
worldwide [23]. Hence, in light of the importance 
of S100A12 diagnosis and the relatively high 
prevalence of gastric cancer in Iran, the goal of this 
study was to investigate the expression of 
S100A12 in tissues of patients with GC and to 
examine the relationship between the expression of 
S100A12 in glandular tissue cells and stromal of 
tumor specimens with clinicopathological features. 
Materials and methods: 
- Sampling and data collection method 
The population of this study consisted of 79 
patients with GC referred to Besat Hospital in 
Hamedan, who had undergone gastrocectomy in 
the period of 2012-17. Demographic and 
pathological data including age, sex, tumor size, 
invasion depth, metastasis, tumor differentiation 
and tumor/nodes/ metastasis (TNM staging system  
References 
14. Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, Ross KF, et al. Anti-infective protective properties 
of S100 calgranulins. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry [Formerly Current 
MedicinalChemistry-Anti-Inflammatory and Anti-Allergy Agents]. 2009;8[4]:290-305.  
15. Meijer B, Gearry R, Day A. The role of S100A12 as a systemic marker of inflammation. International journal of 
inflammation. 2012.  
16. Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of 
inflammatory bowel disease. Inflammatory bowel diseases. 2014;20[4]:742-56. 
17. Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's 
disease. Inflammatory bowel diseases. 2014;20[9]:1668-77.  
18. Pac-Kozuchowska E, Krawiec P, Mroczkowska-Juchkiewicz A. Fecal lactoferrin in identifying and management of 
inflammatory bowel disease. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego. 2014;37[217]:61-4.  
Vafaeie, 2016. The Cancer Press, 2(2)                                                                                             2016. The Cancer Press, 2(2) : 35-38                                                                                                                37 
Vol. 1, Mar, 2019 
S100A12, 2019.The Cancer Press, ,1, 1-14                                                                                                                                            4 
www.imaqpress.com  
www.thecancerpress.com 
) based on UICC classification were collected. The 
objectives of the study were explained to the 
subjects and the informed consents were obtained. 
The formalin-fixed tumor and non-tumor tissues 
were selected. In the next step, paraffin blocks of 
existing biopsies, after cutting by microtome, were 
investigated by immunohistochemistry (IHC) in 
terms of the expression of S100A12 protein.- 
Immunohistochemistry technique: 
The immunohistochemistry was performed in 
conformity with previous standard methods [24]. 
In sum, the deparaffinized tissue sections were 
treated with 3% H2O2 and underwent antigen 
retrieval by citric acid (PH = 6). It was then treated 
overnight at a temperature of 4 °C with a primary 
antibody (anti-S100a12, produced by ABCAM 
Company and obtained from Arjans Co.). In the 
next step, tissue sections were treated at room 
temperature for 15 min by conjugated secondary 
antibody with horseradish peroxidase. Then they 
were treated with diaminobenzidine for 1 min. 
Finally, the sections were stained by hematoxylin 
and the tissue sections that had not treated with the 
primary antibody were considered as the control 
group. - 
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Immunohistochemical staining analysis 
The results of immunohistochemical staining for 
S100A12 protein were analyzed in all sections. In 
this study, S100A12 appeared in cytoplasm of 
tumor cells with varying color intensities. 
Therefore, the expression information of S100A12 
in tumor cells, which was graded by color 
intensity, was analyzed according to the four-row 
grading system [0 = absent, 1 = poor, 2 = medium, 
and 3 = strong staining intensity]. Since S100A12 
protein in stem cells is found in the nucleus and 
cytoplasm, the staining cells were brown and 
calculated independently. Hence, the number of 
cells stained in the stem cells was analyzed as 
immunohistochemistry score (IHC) and then 
divided into three groups based on the percentage 
of positive cells: group 0 (<10%), group +1 (10-
25%); group +2  (> 50%). For further analysis, the 
expression levels of S100A12 were spilt into two 
groups: negative group (score <1 or +1) and 
positive group (score >1 or +1). 
Data analysis 
Following the experiments, all data were collected 
and entered into SPSS V16 software for analysis. 
Chi square tests with 95% confidence intervals 
were used to analyze the relationship between 
S100A12 protein and pathological features. 
Results: 
The study population comprised of GC patients 
referring to Besat Hospital in Hamadan, of whom 
79 were included in this study. The formalin-fixed 
tumor tissues of these subjects were used for 
immunohistochemistry to determine the expression 
in in glandular and stromal cells separately  
After performing immunohistochemical stages and 
observing the resultant samples, the outcomes of 
S100A12 protein were analyzed in all sections by 
an optical microscope with magnification ×200. In 
this study, S100A12 protein was observed in 
cytoplasm of tumor cells, which appeared with 
varying color intensities in different samples of 
patients, suggesting that its expression was 
different in individuals.  
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Further, to determine whether there is any 
significant difference between the expression of 
this protein in tumor and non-tumor tissues, 50 
pairs of tumor and non-tumor tissue samples of 
mucosal epithelial of gastric tissue were randomly 
analyzed. According to the results, there was a 
significant difference in the expression of the 
protein between tumor and non-tumor tissues, in a 
way that tumor cells exhibited lower expression 
than non-tumor cells [48.5% in tumor cells 
compared to 87.7% in non-tumor cells at a 
significant level of (P <0.001) (Fig. 1). 
In this paper, the link between the expression of 
S100A12 cytoplasmic protein expression in 
glandular and stromal tumor cells and 
clinicopathological features of the samples was 
analyzed. The results are presented in Table 1 and 
2. In the present study, out of 79 samples, 55 
(69.6%) showed negative expression of S100A12 
protein in glandular cells, whereas 24 (30.4%) 
exhibited the positive expression of this protein in 
the same cells The findings suggested a significant 
relationship between the expression of S100A12 in 
glandular cells and the degree of tumor 
differentiation, meaning that cells with a weaker 
degree of differentiation exhibited a lower protein 
expression (P <0.001). It should be noted that cells 
with a weaker degree of differentiation are in more 
advanced stages of the disease. Moreover, there 
was a significant difference between the size of the 
tumor (P <0.02) and TNM stage (P <0.004), but 
S100A12 protein and other clinicopathological 
features such as age, sex and metastasis to lymph 
nodes were not significantly correlated (P> 0.05) 
(Table 1). 
In this study, out of 79 samples, 16 (20.3%) 
displayed a negative expression of S100A12 
protein in stromal cells of tumor samples while 63 
(79.7%) showed a positive expression of this 
protein in the same cells  
However, the results of statistical analysis revealed 
that the expression of S100A12 protein in stromal 
cells of tissue samples and clinicopathological 
features of participants such as age, sex, tumor 
size,  
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-depth of tumor invasion, metastasis to lymph 
nodes, TNM stage, and degree of cell 
differentiation were not significantly correlated 
(P> 0.05) (Table 2). Comparing the expression of 
S100A12 protein in glandular and stromal tissue 
cells in patients with gastric cancer did not suggest 
a significant relationship between the expression of 
such protein in these cells (p = 0.306) (Table 3). 
Table 1: Relationship between expression of S100 A12 protein and glandular tissue cells in GC patients 
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S100A12 expression in Glandular tumor 
cells 
  
p-Value Positive Negative All 
cases 
Clinicopathological features 
  
0.270 
20[34.5%] 38[65.5%] 58 Male Gender 
4[19.0%] 17[81.0%] 21 Female 
  
0.777 
6[4.03%] 49[85.9%] 57 <57   
Age at diagno-
sis [years] 
1[4.5%] 21[95.45%] 22 ≥57 
  
0.485 
50[38.29%] 29[61.7%] 47 <4.5   
Size [cm] 56[28.12%] 23[71.87%] 32 ≥4.5 
  
0.001< 
19[59.3%] 13[40.7%] 32 Well   
Differentiation 
  
6[26.1%] 17[73.9%] 23 Moderately 
0[0.0%] 22[100%] 22 Poorly and undif-
ferentiated 
  
  
4[57.1%] 3[42.9%] 7 T1   
Depth of inva-
sion 
1[16.7%] 5[83.3%] 6 T2 
28[25.8%] 47[74.2%] 66 T3/T4 
  10[40.0%] 15[60.0%] 25 N0   
Nodal me-
tastasis 
16[29.7%] 38[70.3%] 54 N1/N2/N3 
www.imaqpress.com  
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S100A12 expression in  stromal tumor 
cells 
  
p-Value Positive Negative All 
cases 
Clinicopathological features 
  
0.479 
44[75.9%] 14[24.1%] 58 Male Gender 
19[90.5%] 2[9.5%] 21 Female 
  
0.742 
42[73.68%] 15[26.31%] 57 <57   
Age at diagno-
sis [years] 
20[90.90%] 2[9.09%] 22 ≥57 
  
0.532 
40[85.10%] 7[14.89%] 47 <4.5   
Size [cm] 
23[71.87%] 9[28.12%] 32 ≥4.5 
  
0.095 
27[81.5%] 5[18.5%] 32 Well   
Differentiation 
18[78.3%] 5[21.7%] 23 Moderately 
18[81.8%] 4[18.2%] 22 Poorly and undifferen-
tiated 
  7[100%] 0[0.0%] 7 T1 Depth of invasion 
5[83.3%] 1[16.7%] 6 T2 
55[83.4%] 11[16.6%] 66 T3/T4 
  21[84.0%] 4[16.0%] 25 N0 Nodal metasta-
sis 44[81.5%] 10[18.5%] 54 N1/N2/N3 
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Table 3: Relationship between expression of S100A12 protein in stromal and glandular tissue cells in subjects 
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  glandular expression Total 
0 1 
stromal 
expres-
sion 
0 Count 13 3 16 
% within stromal expression 81.2% 18.8% 100.0% 
1 Count 24 12 36 
% within stromal expression 66.7% 33.3% 100.0% 
2 Count 11 8 19 
% within stromal expression 57.9% 42.1% 100.0% 
3 Count 7 1 8 
% within stromal expression 87.5% 12.5% 100.0% 
Total Count 55 24 79 
% within stromal expression 69.6% 30.4% 100.0% 
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Figure: Immunohistochemical staining of S100A12 protein in cancer  tissue samples in patients with GC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*brown: [IHC staining] 
*Purple: [H & E staining] [×200] 
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Discussion: 
Several proteins belonging to the group of calcium
-binding proteins (i.e. S100) have been  identified 
so far. The expression level of these proteins in 
relation to tumor progression has received growing 
scholarly attention. In this regard, the relationship 
between various S100 proteins and gastric cancer 
(GC) has been investigated in various research. 
Among these proteins, some subunits have been 
used as biomarkers in GC. Zhang reported that 
serum levels of S100A6 in GC patients were 
remarkably higher than that of healthy subjects (P 
<0.001), which could be used as a diagnostic 
biomarker in gastric cancer. S100A6 inhibition 
restricts metastatic ability of cells containing 
S100A6 [25, 22]. Conversely, a meta-analysis has 
shown that an increase in the expression of 
S100A4 may lead to poor prognosis in Asian 
patients with GC, but this protein could be a useful 
marker for assessing the progression and diagnosis 
of patients with GC [4].The Kaplan-Meier analysis 
showed a lower survival rate for patients with 
moderate or poor S100A4 expression than those 
without S100A4 expression (P <0.001). There was 
also a correlation between depth of tumor invasion, 
metastasis to lymph nodes, TNM, and S100A4 
expression, with these factors acting as a criterion 
for poor prognosis of patients (P <0.05). Increased 
expression of S100A4 is directly related to 
pathogenesis, growth, invasion, metastasis and 
differentiation of gastric carcinoma. Therefore, 
S100A4 can be an indication of aggressive 
behavior and progression of gastric carcinoma. 
Recent studies have shown that lower expression 
of S100A12 is associated with the deterioration of 
gastric cancer. In addition, S100A12 has lower 
expression in GC tissue samples compared to non-
cancerous gastric tissues [26].   
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In our study, the analysis of S100A12 protein 
expression in the cytoplasm of tissue samples in 
patients was performed by immunohistochemistry 
(IHC) technique. This technique has already been 
used for S100A14 and S100A16 proteins in breast 
cancer as a way of detecting protein expression 
[19]. The relationship between S100A12 
expression in glandular and stromal tumor cell 
samples of 79 patients with GC and their 
clinicopathological features were analyzed. 69.6% 
of patients had negative expression of S100A12 
protein in glandular cells, while 30.4% had 
positive expression of this protein in the same 
cells. In addition, the results showed there was a 
significant difference between tumor and non-
tumor tissues in the expression of the target 
protein, so that tumor cells exhibited lower 
expression than non-tumor cells. The results also 
suggested a significant relationship between 
expression of S100A12 protein in glandular cells 
and degree of tumor differentiation. Moreover, 
there was a significant relationship between tumor 
size (P <0.02) and TNM stage (P <0.004), but 
S100A12 protein and other clinicopathological 
features such as age, sex and metastasis to lymph 
nodes (P> 0.05) were not significantly correlated. 
Table [1-3], in agreement with the results of our 
study, shows that S100A12 protein can be helpful 
to identify GC patients with lower invasive 
severity and to evaluate the progression of GC 
tumors. Also in this study, a significant positive 
accumulation of S100A12 in stromal cells was 
observed under tumor cells. Stromal cells, which 
have positive S100A12 expression, often exhibit 
higher levels of immune activity. In these cells, 
immune cells with a myelogenous source have a 
more active presence, which indicate cancer-
induced inflammationIn our research, of 79 
samples, 20.3% had negative expression of 
S100A12 protein in stromal cells of tumor 
samples, while 79.7% had positive expression of 
this protein in the same cells. The results of 
statistical analysis did not show any significant 
correlation between the expression of S100A12 
protein in stromal cells of tissue samples and the 
clinicopathological features of patients such as age,  
.  
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sex, tumor size, tumor invasion depth and 
metastasis to lymph nodes, TNM stage and degree 
of cell differentiation (P> 0.05). The results of our 
study are consistent with those reported by Dan Li 
et al., 2016. In this study, which explored the 
expression of S100A12 protein in 207 patients 
with gastric cancer in China using 
immunohistochemistry, it was found that 64.25% 
of glandular tumor cells had positive protein 
expression, and in the case of stromal cells, the 
expression level of this protein was 48.86%. 
Therefore, in GC, the protein expression of 
S100A12 increased compared to non-cancerous 
tissues (p <0.05). The expression of S100A12 was 
inversely correlated with tumor size (p = 0.004), 
invasion depth (p = 0.022), TNM stage (p = 0.018) 
and cell differentiation (p <0.000). Survival 
analysis indicated that S100A12 protein was a 
factor affecting the prognosis of GC [22]. The 
researchers exhibited that serum levels of S100A6, 
a member of the S100 family, were significantly 
associated with the TNM stage, metastases of 
lymph nodes and depth of invasion, and it may be 
considered as a diagnostic biomarker in GC [3].In 
the study of Ji Liu in 2008 [5], the modified 
expression of the S100 family genes in normal and 
malignant stomach tissues was compared. Among 
genes studied, S100A2, S100A4, S100A7 and 
S100A3 genes had higher expression in gastric 
cancer. There was a 2.5-fold increase in the 
expression of S100A3 compared to non-tumor 
tissues and its expression was correlated with 
tumor differentiation and TNM stage, which is not 
in line with the results of the present research. The 
findings reported by Fan in 2012 [27] are also 
contradictory with our results. 
Conclusion: Our results suggested that low 
expression of S100A12 protein could be used as a 
biomarker for diagnosis of gastric cancer and its 
progression. However, further research is needed 
to shed more light on its mechanism. 
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